Bringing innovative drugs and biologics to the U.S. market can require years of clinical development, regulatory review, and evidence generation. For products addressing serious diseases and unmet medical needs, the U.S. Food and Drug Administration (FDA) offers expedited approval pathways designed to accelerate development, review, and patient access while maintaining appropriate standards for safety and effectiveness. For pharmaceutical, biotech, clinical research, and regulatory teams, understanding how to strategically use these programs can create significant development advantages.

FDA’s four major expedited programs for drugs and biologics are Fast Track designation, Breakthrough Therapy designation, Accelerated Approval, and Priority Review. Although they share the goal of speeding development or review, each has different eligibility criteria and regulatory benefits. A product may qualify for more than one program when the applicable requirements are met. Fast Track designation is intended for drugs that treat serious conditions and have the potential to address an unmet medical need. Its benefits can include more frequent FDA interactions, written communications regarding development issues, eligibility for rolling review, and potential eligibility for Accelerated Approval and Priority Review. Sponsors should seek Fast Track designation early enough to integrate FDA feedback into the clinical development strategy rather than treating designation as simply a faster review mechanism.

Breakthrough Therapy designation provides a more intensive development approach when preliminary clinical evidence indicates that a drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. The program can provide intensive FDA guidance, organizational commitment from senior managers, and opportunities for more efficient development planning. The evidentiary threshold is therefore more demanding than simply demonstrating potential to address an unmet need. Accelerated Approval is particularly important when traditional clinical benefit endpoints would require substantial time to measure. Under this pathway, approval may be based on a surrogate endpoint reasonably likely to predict clinical benefit or an appropriate intermediate clinical endpoint. However, accelerated approval is not an exemption from evidence requirements. Sponsors generally must conduct post-approval confirmatory studies to verify clinical benefit, and FDA has authority to take action, including withdrawal of approval, when requirements are not satisfied.

Priority Review focuses primarily on reducing FDA review time rather than shortening the clinical development program. FDA’s goal is generally to take action within six months for a Priority Review application compared with ten months under standard review. To qualify, an application must meet applicable criteria, such as demonstrating a significant improvement in safety or effectiveness for a serious condition. Priority Review does not reduce FDA’s scientific standards or the quality of evidence expected in an application. For sponsors seeking to maximize these incentives, the most effective approach is to build an FDA regulatory strategy around the product’s scientific profile from the earliest stages of development. The seriousness of the disease, existing treatment landscape, unmet medical need, preliminary clinical evidence, endpoint selection, biomarker strategy, and feasibility of confirmatory studies should all be considered before requesting a designation. Early regulatory interactions can help identify evidence gaps and prevent expensive development changes later.

A strong drug development strategy should also distinguish between development acceleration and review acceleration. Fast Track and Breakthrough Therapy designation can influence development interactions, while Priority Review primarily affects application review. Accelerated Approval can potentially shorten the time to approval by allowing reliance on appropriate surrogate or intermediate endpoints, but it creates significant post-approval obligations. Treating all four programs as interchangeable can result in unrealistic timelines and regulatory planning errors. Recent FDA activity reinforces the importance of disciplined execution. FDA reported that 72% of novel drugs approved in 2025 used at least one expedited development or review program, demonstrating how important these mechanisms have become in modern FDA approval pathways. At the same time, FDA continues to emphasize post-approval obligations associated with Accelerated Approval. A 2025 draft guidance discusses considerations for determining whether required confirmatory trials are “underway,” reflecting increased attention to timely verification of clinical benefit.

For medical device companies, the regulatory framework is different. FDA’s Breakthrough Devices Program applies to certain devices and device-led combination products intended for life-threatening or irreversibly debilitating diseases or conditions. Eligible products may receive prioritized review and enhanced opportunities for interaction with FDA during development. Importantly, designation does not lower FDA’s safety and effectiveness standards. The major compliance risk is assuming that an expedited pathway guarantees approval. It does not. Sponsors remain responsible for generating reliable evidence, maintaining appropriate clinical and manufacturing controls, meeting reporting obligations, and communicating accurately with FDA. For Accelerated Approval products, delays or deficiencies in confirmatory studies can create substantial regulatory and commercial consequences. Companies should therefore maintain a documented regulatory compliance framework covering commitments, milestones, data integrity, protocol execution, and FDA communications.

From a practical perspective, companies can gain the most value by selecting the right program at the right development stage, preparing a scientifically persuasive designation request, using FDA meetings strategically, aligning endpoints with the intended pathway, and planning post-approval obligations before submission. A coordinated approach involving clinical, regulatory, biostatistical, medical, quality, and commercial teams can make expedited pathways more effective while reducing avoidable compliance risks. For organizations seeking a deeper understanding of how to strategically use these opportunities, the FDA regulatory consulting webinar “How to Make the Most of FDA’s Expedited Approval Pathways” provides a practical framework for maximizing available incentives while maintaining regulatory discipline.